Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma
Authors
Keywords
-
Journal
JAMA Oncology
Volume -, Issue -, Pages -
Publisher
American Medical Association (AMA)
Online
2022-12-09
DOI
10.1001/jamaoncol.2022.5816
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors
- (2022) Adam C. Palmer et al. CLINICAL CANCER RESEARCH
- Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2)
- (2022) Jianming Xu et al. Nature Communications
- Efficacy and activity of PD-1 blockade in patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis with focus on the value of PD-L1 combined positive score
- (2022) A.G. Leone et al. ESMO Open
- KMSubtraction: reconstruction of unreported subgroup survival data utilizing published Kaplan-Meier survival curves
- (2022) Joseph J. Zhao et al. BMC Medical Research Methodology
- Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study
- (2022) Lin Shen et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score
- (2022) Barbara Burtness et al. JOURNAL OF CLINICAL ONCOLOGY
- Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial
- (2022) Zhihao Lu et al. BMJ-British Medical Journal
- Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy
- (2022) Joe Yeong et al. Gastric Cancer
- IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves
- (2021) Na Liu et al. BMC Medical Research Methodology
- Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition
- (2021) Raghav Sundar et al. GUT
- Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma
- (2021) Huiyan Luo et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Low Programmed Death-Ligand 1–Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma
- (2021) Joseph J. Zhao et al. JOURNAL OF CLINICAL ONCOLOGY
- Programmed Death Ligand 1 Heterogeneity and its Impact on Benefit from Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer
- (2020) Lingzhi Hong et al. Journal of Thoracic Oncology
- Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study
- (2020) Jing Huang et al. LANCET ONCOLOGY
- Mutational Characterization and Potential Prognostic Biomarkers of Chinese Patients with Esophageal Squamous Cell Carcinoma
- (2020) Nan Zhang et al. OncoTargets and Therapy
- Gene Expression Profiling Reveals Distinct Molecular Subtypes of Esophageal Squamous Cell Carcinoma in Asian Populations
- (2019) Fengling Wang et al. NEOPLASIA
- Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
- (2019) Ken Kato et al. LANCET ONCOLOGY
- RoB 2: a revised tool for assessing risk of bias in randomised trials
- (2019) Jonathan A C Sterne et al. BMJ-British Medical Journal
- 785TiPPhase III KEYNOTE-590 study of chemotherapy + pembrolizumab versus chemotherapy + placebo as first-line therapy for patients (Pts) with advanced esophageal or esophagogastric junction (E/EGJ) cancer
- (2018) K Kato et al. ANNALS OF ONCOLOGY
- Checkmate 649: A randomized, multicenter, open-label, phase 3 study of nivolumab (Nivo) plus ipilimumab (Ipi) versus oxaliplatin plus fluoropyrimidine in patients (Pts) with previously untreated advanced or metastatic gastric (G) or gastroesophageal junction (GEJ) cancer.
- (2017) Yelena Yuriy Janjigian et al. JOURNAL OF CLINICAL ONCOLOGY
- Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data
- (2015) Lesley A. Stewart et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves
- (2012) Patricia Guyot et al. BMC Medical Research Methodology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now